Prostate Cancer Treatment Guidelines

Introduction to Treatment Options

Prostate cancer treatment options include radical prostatectomy, radiation therapy, and active surveillance, with the choice of treatment depending on the patient's risk group and life expectancy 1, 2, 3, 4

For patients with very low or low-risk disease and life expectancy >10 years, active surveillance is the preferred management approach, while radical prostatectomy or radiation therapy alone are options for selected patients, as recommended by the National Comprehensive Cancer Network 1, 2
For patients with intermediate-risk disease, both radical prostatectomy and radiation therapy with 4-6 months of androgen deprivation therapy (ADT) are standard treatment options, according to the Journal of Urology 1
For patients with high-risk disease, both radical prostatectomy and radiation therapy with 2-3 years of ADT are standard treatment options, as recommended by the National Comprehensive Cancer Network 1, 2

The SPCG-4 trial showed that at 15 years, radical prostatectomy reduced all-cause mortality (46.1% vs 52.7%) and prostate cancer-specific mortality (14.6% vs 20.7%), as reported in the Journal of Urology 1
Radical prostatectomy showed significantly lower prostate cancer-specific death rates (9.1% vs 17.5%) compared to observation in high-risk patients, according to the Journal of Urology 1
The PIVOT trial showed no significant survival benefit for surgery vs. observation in low-risk patients, as reported by the Annals of Oncology 5

Better long-term cancer control for high-risk disease is an advantage of radical prostatectomy, as stated in the Journal of Urology 1
Allows for better pathological staging and potential adjuvant therapy decisions, as recommended by the National Comprehensive Cancer Network 2
Anastomotic strictures are a potential complication of radical prostatectomy, as noted in the National Comprehensive Cancer Network guidelines 2
Radical prostatectomy causes significant side effects, including erectile dysfunction (80% vs. 45% with observation) and urinary incontinence (49% vs. 21% with observation), as reported by the Annals of Oncology 5

Life expectancy <5 years: Consider observation/watchful waiting, as suggested by the Journal of Urology 1
Life expectancy 5-10 years: Consider less aggressive treatment approaches, according to the National Comprehensive Cancer Network 2
Life expectancy >10 years: Consider definitive treatment with either radical prostatectomy or radiation therapy with ADT, as recommended by the National Comprehensive Cancer Network 2

Very low/low risk: Active surveillance preferred, radical prostatectomy or radiation therapy alone if treatment needed, as recommended by the Journal of Urology and the National Comprehensive Cancer Network 1, 2
Intermediate risk: Radical prostatectomy or radiation therapy with 4-6 months of ADT, according to the Journal of Urology 1
High risk: Radical prostatectomy or radiation therapy with 2-3 years of ADT, as recommended by the Journal of Urology and the National Comprehensive Cancer Network 1, 2

PSA testing every 6 months (unless clinically indicated) for patients on active surveillance, as recommended by the NCCN Guidelines 2
Digital rectal examination every 12 months (unless clinically indicated) for patients on active surveillance, as recommended by the NCCN Guidelines 2
Repeat prostate biopsy within 6 months if initial biopsy was <10 cores for patients on active surveillance, as recommended by the NCCN Guidelines 2
Considering annual repeat biopsies to assess for disease progression for patients on active surveillance, as recommended by the NCCN Guidelines 2
Considering multiparametric MRI if PSA increases and systematic biopsy is negative for patients on active surveillance, as recommended by the NCCN Guidelines 2

Treatment options for disease progression include radical prostatectomy, external beam radiation therapy, and brachytherapy, as reported by the Annals of Oncology 5

Very low-risk prostate cancer patients are suitable for active surveillance, characterized by clinical stage T1c, Gleason score ≤6, PSA <10 ng/mL, <3 positive biopsy cores, ≤50% cancer involvement in any core, and PSA density <0.15 ng/mL/g 1
Most low-risk prostate cancer patients are also suitable, with clinical stage T1-T2a, Gleason score ≤6, and PSA <10 ng/mL 1
Certain patient populations, such as African American patients, those with BMI >35 kg/m², and those with PSA density >0.15 ng/mL, are at higher risk of reclassification to higher risk disease 1

Long-term studies demonstrate the safety of active surveillance, with a cancer-specific mortality rate of 3% at 10-15 years and a metastatic progression rate of <1% at 15 years for very low-risk patients 1
Approximately 20-50% of patients on active surveillance eventually receive treatment within 10 years 1